Literature DB >> 26708020

The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.

Barbora Tomalova1, Milada Sirova2, Pavel Rossmann3, Robert Pola4, Jiri Strohalm5, Petr Chytil6, Viktor Cerny7, Jakub Tomala8, Martina Kabesova9, Blanka Rihova10, Karel Ulbrich11, Tomas Etrych12, Marek Kovar13.   

Abstract

Polymer drug carriers that are based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have been widely used in the development and synthesis of high-molecular-weight (HMW) drug delivery systems for cancer therapy. In this study, we compared linear (Mw ~27kDa, Rh ~4nm) and non-degradable star (Mw ~250kDa, Rh ~13nm) HPMA copolymer conjugates bearing anthracycline antibiotic doxorubicin (DOX) bound via pH-sensitive hydrazone bond. We determined the in vitro and in vivo toxicity of both conjugates and their maximum tolerated dose (MTD). We also compared their anti-tumour activity in mouse B-cell leukaemia (BCL1) and a mouse T-cell lymphoma (EL4) model. We found that MTD was higher for the linear conjugate (85mgDOX/kg) and lower for the star conjugate (22.5mgDOX/kg). An evaluation of the intestinal barrier integrity using FITC-dextran as a gut permeability tracer proved that no pathology was caused by the MTD of either conjugate. However, free DOX showed some damage to the gut barrier. The therapy of BCL1 leukaemia by both of the polymeric conjugates using the MTD or its fraction (i.e., equitoxic dosage) showed better results in the case of the star conjugate. On the other hand, treatment of EL4 lymphoma seemed to be more efficient when the linear conjugate was used. We suppose that the anti-cancer treatment of solid tumours and leukaemias requires different types of drug conjugates. We hypothesise that the most suitable HPMA copolymer-DOX conjugate for the treatment of solid tumours should have an HMW structure with increased Rh that would be stable for three to four days after the conjugate administration and then rapidly disintegrate in the short polymer chains, which are excretable from the body by glomerular filtration. On the other hand, the treatment of leukaemia requires a drug conjugate with a long circulation half-life. This would provide an active drug, whilst slowly degrading to excretable fragments.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-tumour activity; Doxorubicin; HPMA; Structure; Toxicity

Mesh:

Substances:

Year:  2015        PMID: 26708020     DOI: 10.1016/j.jconrel.2015.12.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  5 in total

1.  HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours.

Authors:  Libor Kostka; Lenka Kotrchová; Vladimír Šubr; Alena Libánská; Carolina A Ferreira; Iva Malátová; Hye Jin Lee; Todd E Barnhart; Jonathan W Engle; Weibo Cai; Milada Šírová; Tomáš Etrych
Journal:  Biomaterials       Date:  2019-12-26       Impact factor: 12.479

Review 2.  Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment.

Authors:  Stuart P Atkinson; Zoraida Andreu; María J Vicent
Journal:  J Pers Med       Date:  2018-01-23

3.  Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats.

Authors:  Hoay Yan Cheah; Olivera Šarenac; Juan J Arroyo; Marko Vasić; Maja Lozić; Sofija Glumac; See Ziau Hoe; Charles Colin Thomas Hindmarch; David Murphy; Lik Voon Kiew; Hong Boon Lee; María J Vicent; Lip Yong Chung; Nina Japundžić-Žigon
Journal:  Nanotoxicology       Date:  2017-02-09       Impact factor: 5.913

4.  Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.

Authors:  Yi-Hsien Cheng; Chunla He; Jim E Riviere; Nancy A Monteiro-Riviere; Zhoumeng Lin
Journal:  ACS Nano       Date:  2020-03-04       Impact factor: 15.881

5.  Structure-to-Efficacy Relationship of HPMA-Based Nanomedicines: The Tumor Spheroid Penetration Study.

Authors:  Júlia Kudláčová; Lenka Kotrchová; Libor Kostka; Eva Randárová; Marcela Filipová; Olga Janoušková; Jun Fang; Tomáš Etrych
Journal:  Pharmaceutics       Date:  2020-12-20       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.